期刊文献+

存活素及人类白细胞抗原Ⅰ类分子在肾透明细胞癌中的表达及其临床意义

Expression and significance of Survivin and HLA-Ⅰ in clear cell renal cell carcinoma
下载PDF
导出
摘要 目的探讨凋亡抑制因子survivin和HLA-Ⅰ类分子在人肾透明细胞癌(ccRCC)中的表达及其临床意义。方法应用免疫组化方法检测90例ccRCC组织与10例正常肾组织中survivin及HLA-Ⅰ类分子的表达。结果 10例正常肾组织均未见survivin表达,而HLA-Ⅰ类分子阳性率为100%。survivin阳性表达及HLA-Ⅰ类分子下调在90例ccRCC组织标本中表达分别为74例(82.2%)和61例(67.8%)。survivin的表达率与肿瘤分级及淋巴结转移相关,而HLA-Ⅰ类分子的表达下调与患者年龄、性别、肿瘤分级、分期及淋巴结转移均无关。ccRCC组织中survivin表达与HLA-Ⅰ类分子的表达无相关性。结论 sur-vivin、HLA-Ⅰ类分子异常表达参与了ccRCC的发生、发展过程,可能成为ccRCC的一个重要预后指标和治疗靶点。 Objective To study the expression and significance of survivin and human leukocyte antigen class I(HLA-I) in human clear cell renal cell carcinoma(ccRCC).Methods Immunohistochemical staining was performed on specimens from 10 normal renal tissues and specimens from 90 patients with RCC who underwent radical nephrectomy to detect the expression of survivin and HLA-I.Results Survivin was undetectable while HLA-I was expressed in all normal renal tissues.Survivin was expressed in 74(82.2%) of the 90 renal cancer specimens,and the expression of HLA-Ⅰwas down-regulated in 61(67.8%) specimens.The expression of survivin in ccRCC was associated with the metastasis and the pathological stages.But the expression of HLA-Ⅰ had no correlation with other clinicopathological parameters such as tumor size,perirenal fat invasion,age,TNM stage or nuclear grade.The expression of survivin was not correlated with that of HLA-Ⅰ in ccRCC.Conclusions Survivin and HLA-Ⅰmay play an important role in the occurrence and progression of ccRCC,which may be an important diagnostic/therapeutic indicator or target in ccRCC.
出处 《现代泌尿外科杂志》 CAS 2012年第1期24-27,共4页 Journal of Modern Urology
基金 黑龙江省卫生厅科研基金资助项目(No.2007-197) 黑龙江省政府博士后资助基金(No.LRB09-407) 哈医大一院科研基金资助项目(No.2007-086)
关键词 肾透明细胞癌 SURVIVIN HLA-Ⅰ类分子 免疫组织化学 免疫治疗 clear cell renal cell carcinoma survivin HLA-I immunohistochemistry immunotherapy
  • 相关文献

参考文献9

  • 1MITA AC,MITA MM,NAWROKI ST,et al. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics[J].Clin Cancer Res,2008,14(16):5000-5005.
  • 2李凌霞,王桂琴.HLA异常表达与恶性肿瘤[J].山西医科大学学报,2007,38(6):562-565. 被引量:1
  • 3KITAMURA H,TORIGOE T,HONMA I,et al. Expression and antigenicity of survivin,an inhibitor of apoptosis family member,in bladder cancer: implications for specific immunotherapy[J].Urology,2006,67(5):955-959.
  • 4KITAMURA H,HONMA I,TORIGOE T,et al. Down-Regulation of HLA Class I Antigen is an Independent Prognostic Factor for Clear Cell Renal Cell Carcinoma[J].J Urol,2007,177(4):1269-1272.
  • 5AMBROSINI G,ADIDA C,ALTIERI DC,et al. A novel antiapoptosis gene, Survivin,expressed in cancer and lymphoma[J].Nat Med,1997,3(8):917-921.
  • 6WANG GC,HSIEH PS,HSU HH,et al. Expression of cortactin and survivin in renal cell carcinoma associated with tumor aggressiveness[J]. World J Urol,2009,27(4):557-563.
  • 7LU J,TAN M,HUANG WC,et al. Mitotic deregulation by Survivin in ErbB2-overexpressing breast cancer cells contributes to Taxol resistance[J]. Clin Cancer Res, 2009,15(4):1326-1334.
  • 8SMITH SD,WHEELER MA,PLESCIA J,et al. Urine detection of surviving and diagnosis of bladder cancer[J].JAMA,2001,285(3):324-328.
  • 9STICKEL JS,STICHEL N,Hennenlotter J,et al. Quantification of HLA class I molecules on renal cell carcinoma using Edman degradation[J]. BMC Urology, 2011,11:1.

二级参考文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部